Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Tehran University of Medical Sciences | OTHER |
Not provided
Not provided
Not provided
Glioblastoma multiform is one of the most invasive and deadly cancers that progresses rapidly and leads to death. Surgery with radiotherapy /chemotherapy, as a treatment approach is ineffective in some cases and is associated with relapse and death. Immunotherapy is a special strategy that used as an adjunct therapy in various cancers and among the various methods of immunotherapy; it seems that cell therapy with NK cells is of special importance. A previous study conducted at the Royan Research Institute showed that NK cell proliferation and amplification resulted in the removal of glioblastoma tumor masses in the animal model. The animals had no evidence of tumor recurrence after treatment, and all tumor-related complications resolved after treatment. Therefore, in this study, the investigators intend to evaluate the safety of ex vivo activated cells in 5 patients with glioblastoma multiform whose disease has returned after treatment and who have not had any appropriate treatment.
1- patient selection 2- leukapheresis 3- CD56+ cells isolation 4- NK cells activation 5- assessment of functionality and purity 6- quality control tests 7-NK cell injection in tumor cavity.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Test group | Experimental | The investigators will inject the activated NK cells, 1-3 times with weekly interval into tumor cavity. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| NK cell therapy | Biological | Activated NK cell injection in tumor cavity of patient with GBM (Glioblastoma Multiform) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Toxicity assay | Toxicity as assessed by NCI CTCAE version 3.0 | 4 weeks of last injection |
| Adverse Events (AEs) | Defined as the number and severity of adverse events | 1 year |
| Safety evaluation | Safety evaluated by assessing the medical symptoms measurement: Fever, Hysteria and Convulsion | From injection time point up to 48 hours |
| Safety evaluation | Safety evaluated by assessing the medical symptoms measurement: Meningitis, Neurological disorders | 2 months after injection |
| Safety evaluation | Safety evaluated by assessing the medical symptoms measurement: Loss of consciousness | From injection time point up to 8 weeks |
| MRI and MRS from the tumor region | Defined tumoral residua and tumor cell recurrence | 1 months after last dose of NK cell injection up to 1 year each 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| Patient survival | Evaluation of patient's life extension followed by NK cell therapy | After surgery up to an average of 1 year |
Not provided
Age: 3-60 Year -
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Marzieh Ebrahimi, PhD | Contact | +98 21 235 62516 | marzieh.ebrahimi@gmail.com;mebrahimi@royan-rc.ac.ir | |
| Zohreh Habibi, M.D | Contact | +98 912 336 5598 | z-habibi@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Niloufar Shayan Asl, MSc | Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran | Principal Investigator |
| Monire Mohammad, MSc | Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Royan institute | Recruiting | Tehran | Postal code:1665659911 | Iran |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D005909 | Glioblastoma |
| ID | Term |
|---|---|
| D001254 | Astrocytoma |
| D005910 | Glioma |
| D018302 | Neoplasms, Neuroepithelial |
| D017599 | Neuroectodermal Tumors |
Not provided
Not provided
The investigators will enroll 5 patients (3-60 year, both sex, -Lansky performance scale/Karnofsky performance scale: 70-100%) with recurrent Glioblastoma Multiform. A haploidentical donor will enter for each patient.
Not provided
Not provided
Not provided
Not provided
| Amirali Hamidieh, MD,PhD | Pediatric cell therapy research center, Tehran University of Medical Sciences | Principal Investigator |
| Marzieh Ebrahimi, PhD | Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran | Study Director |
| Zohreh Habibi, M.D | Children's Hospital Medical Center, Tehran University of Medical Science, Tehran, Iran | Study Director |
| Abolhossein Shahverdi, PhD | Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran | Study Chair |
| D009373 |
| Neoplasms, Germ Cell and Embryonal |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009380 | Neoplasms, Nerve Tissue |